metoprolol has been researched along with Chronic Disease in 129 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23." | 9.27 | Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. ( Huang, J; Liu, X; Meng, Y; Zhang, R, 2018) |
| "To prospectively evaluate the impact of metoprolol achieved heart rate (HR) on cardiac-motor function and quality of life (QoL) in chronic heart failure (CHF) patients." | 9.24 | A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. ( Cheng, X; Liu, J; Liu, X; Meng, Y, 2017) |
| "To explore the pharmacogenetic effects of the cytochrome P450 (CYP)2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional *4 allele (1846G>A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605)." | 9.19 | An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. ( Balmforth, AJ; Batty, JA; de Boer, RA; Hall, AS; Hjalmarson, Å; Kjekshus, J; van der Harst, P; van Veldhuisen, DJ; Waagstein, F; White, HL; Wikstrand, J, 2014) |
| "To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia." | 9.14 | [Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia]. ( He, BB; Huang, GH; Lü, HS, 2009) |
| "The purpose of this study was to compare the effects of immediate-release (IR) metoprolol and extended-release (XL) metoprolol on measures of heart rate variability in chronic systolic heart failure patients." | 9.12 | Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. ( Aquilante, CL; Binkley, PF; Hatton, PS; Johnson, JA; Pauly, DF; Schofield, RS; Terra, SG, 2006) |
| "Cardiovascular risk and risk reduction were analyzed in five subgroups defined by quintiles (Q) of pretreatment resting HR in the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)." | 9.11 | What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). ( Bermann, G; Deedwania, P; Egstrup, K; Elkayam, U; Gottlieb, S; Gullestad, L; Hjalmarson, A; Kjekshus, J; Rashkow, A; Wedel, H; Wikstrand, J, 2005) |
| "We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month follow-up visit to end of study in two dosage subgroups: one that had reached more than 100 mg of metoprolol CR/XL once daily (high-dose group; n = 1,202; mean 192 mg) and one that had reached 100 mg or less (low-dose group; n = 412; mean 76 mg)." | 9.10 | Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). ( Fagerberg, B; Goldstein, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2002) |
| "To evaluate neurohumoral factors as markers for left-ventricular (LV) antiremodelling from metoprolol treatment in patients with chronic LV systolic heart failure." | 9.10 | Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002) |
| "Acute administration of carvedilol attenuates the vasoconstriction response to adrenergic stimuli when compared with placebo and metoprolol in normal subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor response to adrenergic stimuli when compared with metoprolol in heart failure subjects." | 9.10 | Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect." | 9.10 | Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| " We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking properties, may modulate vascular reactivity to Ang II in patients with chronic heart failure (CHF)." | 9.10 | Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. ( Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ, 2003) |
| "We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)." | 9.10 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. ( Bristow, MR; D'Aloia, A; Dei Cas, L; Metra, M; Muneretto, C; Nodari, S; Robertson, AD, 2002) |
| "The purpose of this study was to determine whether carvedilol's alpha(1)-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF)." | 9.09 | Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. ( Azevedo, ER; Floras, JS; Kubo, T; Newton, GE; Parker, JD, 2001) |
| "6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction | 9.09 | Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. ( Aarsland, T; Fagertun, H; Gullestad, L; Kjekshus, J; Manhenke, C; Skårdal, R; Wikstrand, J, 2001) |
| "To compare the effects of sotalol and metoprolol on heart rate, during isotonic (ITE) and isometric (IME) exercise and daily activities, in digitalized patients with chronic atrial fibrillation." | 9.09 | Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. ( Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001) |
| "This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF)." | 9.09 | Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. ( Böhm, M; Crivaro, M; Elter, T; LaRosee, K; Maack, C; Nickenig, G; Stäblein, A; Wuttke, H, 2001) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 9.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "Ten patients with chronic intermittent claudication were included in a double-blind, randomized cross-over study of placebo, propranolol 80 mg b." | 9.05 | Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. ( Bogaert, MG; Clement, DL, 1983) |
| "To assess gender-, age-, and the dose-related influence of metoprolol on cardiac function, motor function, quality-of-life (QoL), and mental status in Chinese chronic heart failure (CHF) patients." | 7.96 | Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study. ( Cheng, X; Feng, Z; Liu, Q; Meng, Y; Zhu, M, 2020) |
| "This study assessed sex differences in cardiac and motor functions, quality of life (QoL), and mental status in Chinese chronic heart failure (CHF) patients after metoprolol treatment." | 7.91 | Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. ( Meng, Y; Shu, Q; Wu, L; Zhang, Q; Zhang, R, 2019) |
| "Aim - optimization of the treatment of obesity and chronic heart failure (CHF) patients by identifying key factors for the progression of cardiac decompensation and the principles of using metoprolol succinate, taking into account pharmacogenetic aspects in the complex treatment of this comorbidity." | 7.91 | METOPROLOL SUCCINATE: GENETIC ASPECTS OF INDIVIDUAL SENSITIVITY AND EFFICACY IN PATIENTS WITH OBESITY AND CHRONIC HEART FAILURE. ( Gasanov, I; Rudyk, Y, 2019) |
| " Here, we investigated the roles of metoprolol in regulation of atrial remodeling induced by chronic OSA." | 7.85 | Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. ( Dong, X; Li, H; Li, M; Li, Y; Lu, S; Sun, L; Wang, X; Wang, Y; Yan, S; Yu, S; Zhao, J; Zhao, S, 2017) |
| "We investigated the influence of metoprolol on gap junction proteins connexin43 (Cx43) and connexin40 (Cx40) in atrial tissue from patients with/without atrial fibrillation (AF)." | 7.77 | Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation. ( Boldt, A; Busch, A; Dhein, S; Kostelka, M; Mohr, FW; Pfannmüller, B; Rastan, A; Reutemann, A; Rojas Gomez, DM; Rothe, S; Salameh, A; Seidel, T, 2011) |
| "To investigate the effect of metoprolol on the expression of G protein-coupled receptor kinases 2 (GRK2) in lymphocyte of advanced elderly patients with chronic heart failure." | 7.76 | [Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure]. ( Gao, WQ; Han, CG; Liu, YX; Wang, Q; Yang, TS; Zhao, YX; Zhu, P, 2010) |
| "Obvious elevation of PP is associated with a better response to metoprolol succinate sustained-release tablets in elderly hypertensive patients with chronic heart failure, and 3 months of treatment with the tablets can significantly improve the cardiac function and lower the levels of VEGF, hs-CRP and BNP in these patients." | 7.76 | [Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure]. ( Lin, ZP; Zhang, ZW, 2010) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 7.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "To define the effects of 2 months of metoprolol therapy on cardiac function, aerobic performance and sympathetic nervous system activity, metoprolol (75 to 100 mg/day) was administered to 10 patients with chronic congestive heart failure (CHF)." | 7.68 | Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. ( Abrass, IB; Nemanich, JW; Stratton, JR; Veith, RC, 1990) |
| "Metoprolol CR/XL was well tolerated in all 3 renal function subgroups." | 6.74 | The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). ( Fagerberg, B; Ghali, JK; Goldstein, S; Hjalmarson, A; Johansson, P; Kjekshus, J; Ohlsson, L; Samuelsson, O; Van Veldhuisen, DJ; Waagstein, F; Wedel, H; Wikstrand, J, 2009) |
| "The origin of thromboembolism is often the left atrial appendix (LAA)." | 6.73 | Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation. ( Akbulut, M; Arslan, N; Balin, M; Coşkun, N; Dağli, N; Ilkay, E; Işik, A; Karaca, I; Yavuzkir, M, 2007) |
| " Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol." | 6.73 | Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. ( Ahuja, K; Hirsh, DS; Jorde, UP; Kasper, ME; Khandwalla, RM; Tseng, CH; Vittorio, TJ; Zolty, R, 2008) |
| " Based on this evidence, it is now recommended to add beta-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis." | 6.43 | The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. ( De Freitas, O; Fornoni, A; Lenz, O; Materson, BJ, 2006) |
| "We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure." | 6.20 | Beta-blocker benefit according to severity of heart failure. ( Bouzamondo, A; Hulot, JS; Lechat, P; Sanchez, P, 2003) |
| "From February 2013 to April 2016, CHF patients with clinical mental disorders received metoprolol (23." | 5.27 | Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders. ( Huang, J; Liu, X; Meng, Y; Zhang, R, 2018) |
| "Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina." | 5.27 | Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases. ( Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J, 1987) |
| "To prospectively evaluate the impact of metoprolol achieved heart rate (HR) on cardiac-motor function and quality of life (QoL) in chronic heart failure (CHF) patients." | 5.24 | A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. ( Cheng, X; Liu, J; Liu, X; Meng, Y, 2017) |
| "To explore the pharmacogenetic effects of the cytochrome P450 (CYP)2D6 genotype in patients with systolic heart failure treated using controlled/extended-release (CR/XL) metoprolol, this study assessed the CYP2D6 locus for the nonfunctional *4 allele (1846G>A; rs3892097) in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF; n = 605)." | 5.19 | An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. ( Balmforth, AJ; Batty, JA; de Boer, RA; Hall, AS; Hjalmarson, Å; Kjekshus, J; van der Harst, P; van Veldhuisen, DJ; Waagstein, F; White, HL; Wikstrand, J, 2014) |
| "To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia." | 5.14 | [Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia]. ( He, BB; Huang, GH; Lü, HS, 2009) |
| "to study the safety of switching from short-acting metoprolol to long-acting bisoprolol in patients with cardiac failure and postinfarction impaired left ventricular systolic function." | 5.13 | Switching beta-blocker therapy in chronic heart failure. ( Somlói, M; Toldy-Schedel, E; Tomcsányi, J; Wettstein, A, 2008) |
| "The purpose of this study was to compare the effects of immediate-release (IR) metoprolol and extended-release (XL) metoprolol on measures of heart rate variability in chronic systolic heart failure patients." | 5.12 | Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. ( Aquilante, CL; Binkley, PF; Hatton, PS; Johnson, JA; Pauly, DF; Schofield, RS; Terra, SG, 2006) |
| "In routine clinical practice in the management of angina (with or without coexisting hypertension), S-metoprolol administered at half the dose of the racemate, shows similar efficacy, safety and a trend towards a higher response rate." | 5.12 | Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina. ( Aneja, P; Biswas, AD; Srinivas, A, 2007) |
| "The purpose of the study was to evaluate the influence of metoprolol succinate and carvedilol on the physical ability (FA) of patients with chronic heart failure (CHF) of different etiologies." | 5.12 | [The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]. ( Andreev, DA; Kalashnikov, VIu; Poltavskaia, MG; Sarkisova, EA; Svet, AV; Syrkin, AL, 2007) |
| "Cardiovascular risk and risk reduction were analyzed in five subgroups defined by quintiles (Q) of pretreatment resting HR in the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)." | 5.11 | What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). ( Bermann, G; Deedwania, P; Egstrup, K; Elkayam, U; Gottlieb, S; Gullestad, L; Hjalmarson, A; Kjekshus, J; Rashkow, A; Wedel, H; Wikstrand, J, 2005) |
| "Acute administration of carvedilol attenuates the vasoconstriction response to adrenergic stimuli when compared with placebo and metoprolol in normal subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor response to adrenergic stimuli when compared with metoprolol in heart failure subjects." | 5.10 | Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month follow-up visit to end of study in two dosage subgroups: one that had reached more than 100 mg of metoprolol CR/XL once daily (high-dose group; n = 1,202; mean 192 mg) and one that had reached 100 mg or less (low-dose group; n = 412; mean 76 mg)." | 5.10 | Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). ( Fagerberg, B; Goldstein, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J, 2002) |
| "Patients with chronic heart failure were randomized to treatment (double blind) with metoprolol 50 mg twice daily or carvedilol 25 mg twice daily in addition to standard therapy." | 5.10 | Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. ( Chan, SK; Fung, JW; Sanderson, JE; Yeung, LY, 2002) |
| "We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)." | 5.10 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. ( Bristow, MR; D'Aloia, A; Dei Cas, L; Metra, M; Muneretto, C; Nodari, S; Robertson, AD, 2002) |
| "To evaluate neurohumoral factors as markers for left-ventricular (LV) antiremodelling from metoprolol treatment in patients with chronic LV systolic heart failure." | 5.10 | Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002) |
| " We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking properties, may modulate vascular reactivity to Ang II in patients with chronic heart failure (CHF)." | 5.10 | Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. ( Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ, 2003) |
| "Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect." | 5.10 | Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| "The prognostic significance of ambulatory ischemia, alone and in relation to ischemia during exercise was assessed in 686 patients (475 men) with chronic stable angina pectoris taking part in the Angina Prognosis Study In Stockholm (APSIS), who had 24-hour ambulatory electrocardiographic registrations and exercise tests at baseline (n = 678) and after 1 month (n = 607) of double-blind treatment with metoprolol or verapamil." | 5.09 | Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 1999) |
| "To compare the effects of sotalol and metoprolol on heart rate, during isotonic (ITE) and isometric (IME) exercise and daily activities, in digitalized patients with chronic atrial fibrillation." | 5.09 | Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. ( Igoumenidis, NE; Kalebubas, MD; Kanoupakis, EM; Kochiadakis, GE; Mavrakis, HE; Vardakis, KE; Vardas, PE, 2001) |
| "6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction | 5.09 | Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. ( Aarsland, T; Fagertun, H; Gullestad, L; Kjekshus, J; Manhenke, C; Skårdal, R; Wikstrand, J, 2001) |
| "This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF)." | 5.09 | Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. ( Böhm, M; Crivaro, M; Elter, T; LaRosee, K; Maack, C; Nickenig, G; Stäblein, A; Wuttke, H, 2001) |
| "Thirty-six patients with chronic heart failure were randomized to the nonselective beta-blocker carvedilol or the selective beta-blocker metoprolol (double-blind)." | 5.09 | Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. ( Al-Hesayen, A; Allan, R; Azevedo, ER; Floras, JS; Kelly, S; Kubo, T; Mak, S; Newton, GE; Parker, JD; Schofield, A, 2001) |
| "The purpose of this study was to determine whether carvedilol's alpha(1)-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF)." | 5.09 | Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. ( Azevedo, ER; Floras, JS; Kubo, T; Newton, GE; Parker, JD, 2001) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 5.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "Ten patients with congestive heart failure were given metoprolol (50 mg/day) or placebo during a double-blind, crossover, randomized study." | 5.07 | Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. ( D'Onofrio, F; Gambardella, A; Marrazzo, G; Paolisso, G; Teasuro, P; Varricchio, M; Verza, M, 1992) |
| "In order to evaluate the negative inotropic effects of sotalol, metoprolol, and propranolol in patients with chronic stable angina pectoris, left ventricular ejection fraction (LVEF) was measured with radionuclide angiography and echocardiography." | 5.05 | Beta-blocker therapy evaluated by radionuclide angiography: a study in chronic stable angina. ( Lessem, J, 1982) |
| "Ten patients with chronic intermittent claudication were included in a double-blind, randomized cross-over study of placebo, propranolol 80 mg b." | 5.05 | Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. ( Bogaert, MG; Clement, DL, 1983) |
| "Ninety-nine patients took part in a multicentre, long-term study of metoprolol in the treatment of hypertension." | 5.04 | Results from a multicentre trial of metoprolol and a study of hypertensive patients with chronic obstructive lung disease. ( Assaykeen, TA; Hua, AS; Kincaid-Smith, PS; Nyberg, G, 1978) |
| "The beta1-selective beta-blocking agent Metoprolol gave a significant intraocular pressure decrease in different groups of open angle glaucoma patients in a concentration of 1% and 3%." | 5.04 | The effect of metoprolol on IOP (author's transl). ( Krieglstein, GK, 1978) |
| "To assess gender-, age-, and the dose-related influence of metoprolol on cardiac function, motor function, quality-of-life (QoL), and mental status in Chinese chronic heart failure (CHF) patients." | 3.96 | Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study. ( Cheng, X; Feng, Z; Liu, Q; Meng, Y; Zhu, M, 2020) |
| "Background Whether chronic obstructive sleep apnea ( OSA ) could promote epicardial adipose tissue ( EAT ) secretion of profibrotic adipokines, and thereby contribute to atrial fibrosis, and the potential therapeutic effects of metoprolol remain unknown." | 3.91 | Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea. ( Dai, H; Gong, Y; Han, Y; Li, T; Li, Y; Sheng, L; Sun, L; Xu, J; Yin, S; Yuan, Y; Zhang, Y, 2019) |
| "This study assessed sex differences in cardiac and motor functions, quality of life (QoL), and mental status in Chinese chronic heart failure (CHF) patients after metoprolol treatment." | 3.91 | Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. ( Meng, Y; Shu, Q; Wu, L; Zhang, Q; Zhang, R, 2019) |
| "Aim - optimization of the treatment of obesity and chronic heart failure (CHF) patients by identifying key factors for the progression of cardiac decompensation and the principles of using metoprolol succinate, taking into account pharmacogenetic aspects in the complex treatment of this comorbidity." | 3.91 | METOPROLOL SUCCINATE: GENETIC ASPECTS OF INDIVIDUAL SENSITIVITY AND EFFICACY IN PATIENTS WITH OBESITY AND CHRONIC HEART FAILURE. ( Gasanov, I; Rudyk, Y, 2019) |
| " Here, we investigated the roles of metoprolol in regulation of atrial remodeling induced by chronic OSA." | 3.85 | Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. ( Dong, X; Li, H; Li, M; Li, Y; Lu, S; Sun, L; Wang, X; Wang, Y; Yan, S; Yu, S; Zhao, J; Zhao, S, 2017) |
| "Clinical efficacy and adverse effects of the β-blocking agents, carvedilol, bisoprolol, and metoprolol were analyzed theoretically, and then compared quantitatively, for the purpose of determining their proper use for chronic heart failure." | 3.85 | Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure. ( Fujito, K; Kimura, K; Takayanagi, R; Yamada, Y, 2017) |
| "We investigated the influence of metoprolol on gap junction proteins connexin43 (Cx43) and connexin40 (Cx40) in atrial tissue from patients with/without atrial fibrillation (AF)." | 3.77 | Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation. ( Boldt, A; Busch, A; Dhein, S; Kostelka, M; Mohr, FW; Pfannmüller, B; Rastan, A; Reutemann, A; Rojas Gomez, DM; Rothe, S; Salameh, A; Seidel, T, 2011) |
| "Obvious elevation of PP is associated with a better response to metoprolol succinate sustained-release tablets in elderly hypertensive patients with chronic heart failure, and 3 months of treatment with the tablets can significantly improve the cardiac function and lower the levels of VEGF, hs-CRP and BNP in these patients." | 3.76 | [Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure]. ( Lin, ZP; Zhang, ZW, 2010) |
| "To investigate the effect of metoprolol on the expression of G protein-coupled receptor kinases 2 (GRK2) in lymphocyte of advanced elderly patients with chronic heart failure." | 3.76 | [Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure]. ( Gao, WQ; Han, CG; Liu, YX; Wang, Q; Yang, TS; Zhao, YX; Zhu, P, 2010) |
| " Carvedilol is more effective than Metoprolol for improving the hemodynamics and in attenuating ventricular remodeling after heart failure." | 3.74 | Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. ( Chen, GW; Jiang, ZF; Lin, Y; Wang, LX; Wu, TG; Zhao, Q, 2007) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 3.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "Body weight and plasma norepinephrine, leptin, and insulin levels were measured in 27 subjects with CHF before and after 6 months of beta-adrenergic receptor blockade with carvedilol or long-acting metoprolol." | 3.72 | Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "The present study addressed possible alterations in the pharmacodynamic and pharmacokinetic properties of the beta1-adrenoceptor antagonist metoprolol in experimental hypertension induced by abdominal aortic coarctation (ACo)." | 3.72 | Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ( Di Verniero, C; Höcht, C; Opezzo, JA; Taira, CA, 2004) |
| "Seventy consecutive patients with recurrent unexplained syncope were evaluated by use of an up-right tilt-table test for 45 minutes (with or without an infusion of isoproterenol) in an attempt to reproduce symptoms." | 3.68 | [Malignant vasovagal syncope: its diagnosis and therapeutic trial based on the orthostatism test (the tilt-table test)]. ( Campos Peris, JV; de la Morena, G; García García, J; Jaén Armand, E; López Candel, J; Martínez Sánchez, J; Picó Aracil, F; Ruiz Ros, JA; Salas, J; Sánchez Muñoz, JJ, 1993) |
| "To define the effects of 2 months of metoprolol therapy on cardiac function, aerobic performance and sympathetic nervous system activity, metoprolol (75 to 100 mg/day) was administered to 10 patients with chronic congestive heart failure (CHF)." | 3.68 | Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. ( Abrass, IB; Nemanich, JW; Stratton, JR; Veith, RC, 1990) |
| "7 years), with previously untreated essential hypertension and echocardiographically proven left-ventricular hypertrophy, received metoprolol 200 mg daily over a period of 12." | 3.67 | [Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block]. ( Behr, M; Franz, IW; Ketelhut, R; Wiewel, D, 1986) |
| "Chronic mitral regurgitation (MR) is characterized by adverse ventricular remodeling and progressive LV dysfunction leading to heart failure (HF)." | 2.82 | Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. ( Garg, N; Goel, P; Kapoor, A; Khanna, R; Kumar, S; Sahoo, D; Sinha, A; Tewari, S, 2016) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "Metoprolol CR/XL was well tolerated in all 3 renal function subgroups." | 2.74 | The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). ( Fagerberg, B; Ghali, JK; Goldstein, S; Hjalmarson, A; Johansson, P; Kjekshus, J; Ohlsson, L; Samuelsson, O; Van Veldhuisen, DJ; Waagstein, F; Wedel, H; Wikstrand, J, 2009) |
| " Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol." | 2.73 | Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. ( Ahuja, K; Hirsh, DS; Jorde, UP; Kasper, ME; Khandwalla, RM; Tseng, CH; Vittorio, TJ; Zolty, R, 2008) |
| "The origin of thromboembolism is often the left atrial appendix (LAA)." | 2.73 | Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation. ( Akbulut, M; Arslan, N; Balin, M; Coşkun, N; Dağli, N; Ilkay, E; Işik, A; Karaca, I; Yavuzkir, M, 2007) |
| "Carvedilol treatment of hibernating myocardium results in improved functional recovery after revascularization compared with metoprolol tartrate, and this might partially be related to reduced cardiomyocyte degeneration." | 2.71 | Carvedilol improves myocardial contractility compared with metoprolol in patients with chronic hibernating myocardium after revascularization. ( Diep, TP; Grohmann, B; Gupta, R; Kostin, S; Nowak, B; Schaper, J; Schwarz, ER; Uretsky, BF, 2005) |
| "Metoprolol was administered to 29 patients, and carvedilol to 62." | 2.70 | Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. ( Hanatani, A; Hirooka, K; Hori, M; Ishida, Y; Komamura, K; Miyatake, K; Nakatani, S; Yamagishi, M; Yasumura, Y, 2001) |
| "With carvedilol, there was a parallel decline from 4." | 2.69 | Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. ( Buchholz-Varley, C; Charney, RH; Eng, C; Kalman, J; Kukin, ML; Levy, DK; Ocampo, ON, 1999) |
| "All patients clinically had idiopathic dilated cardiomyopathy; however, at coronary angiography, four had occult coronary disease." | 2.65 | Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. ( Anderson, ST; Currie, PJ; Federman, J; Harper, RW; Kelly, MJ; Lim, YL; McKenzie, A; Pitt, A, 1984) |
| " Based on this evidence, it is now recommended to add beta-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis." | 2.43 | The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. ( De Freitas, O; Fornoni, A; Lenz, O; Materson, BJ, 2006) |
| " Pharmacokinetic and pharmacodynamic analyses, however, indicate that the dosing regimen of metoprolol selected for use in the COMET trial produces a magnitude and time course of beta(1)-blockade during a 24-hour period that is similar to the dose of carvedilol targeted for use in the trial." | 2.42 | Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. ( Packer, M, 2003) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "Treatment with metoprolol prevented MR-associated oxidation of NO biosensor soluble guanylyl cyclase (sGC) within NLR." | 1.42 | Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy. ( Balligand, JL; Baskharoun, MM; Cannavo, A; Dell'Italia, LJ; Dillon, AR; Houser, SR; Jarrett, H; Koch, WJ; Liu, Y; McCormick, RC; Nanayakkara, G; Recchia, FA; Tillson, DM; Trappanese, DM; Tsai, EJ; Woitek, FJ, 2015) |
| "The therapy for chronic migraine with botulinum toxin is now established in adults." | 1.40 | [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology]. ( Bernhard, MK; Bertsche, A; Merkenschlager, A; Syrbe, S; Weise, S, 2014) |
| "Fifty consecutive patients with dilated cardiomyopathy in NYHA class II-IV with a left ventricular ejection fraction (LVEF) of 35% or below were studied with full polysomnography over one night." | 1.34 | Does beta-blocker treatment influence central sleep apnoea? ( Köhnlein, T; Welte, T, 2007) |
| "On treatment with propylthiouracil and a beta-blocking agent, her symptoms resolved within one day, even though her free thyroxine level was still high." | 1.32 | Hyperthyroidism as a cause of persistent vomiting. ( Cools, BM; Hoogendoorn, EH, 2004) |
| " All centres were provided with carvedilol, metoprolol, and bisoprolol at appropriate doses; the choice of the drug and dosage was left to the responsible clinician." | 1.32 | Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. ( Balli, E; Geraci, E; Gorini, M; Gronda, E; Lucci, D; Maggioni, AP; Opasich, C; Sinagra, G; Tavazzi, L; Tognoni, G, 2003) |
| "Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina." | 1.27 | Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases. ( Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (12.40) | 18.7374 |
| 1990's | 16 (12.40) | 18.2507 |
| 2000's | 67 (51.94) | 29.6817 |
| 2010's | 27 (20.93) | 24.3611 |
| 2020's | 3 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Manoury, PM | 1 |
| Binet, JL | 1 |
| Rousseau, J | 1 |
| Lefèvre-Borg, F | 1 |
| Cavero, IG | 1 |
| Wu, L | 3 |
| Zhang, Q | 3 |
| Shu, Q | 3 |
| Zhang, R | 4 |
| Meng, Y | 6 |
| Yang, L | 1 |
| Zhao, J | 2 |
| Qu, Y | 1 |
| Sun, Q | 1 |
| Li, TT | 1 |
| Yan, ML | 1 |
| Duan, MJ | 1 |
| Li, KX | 1 |
| Wang, YR | 1 |
| Huang, SY | 1 |
| Zhang, S | 1 |
| Li, Y | 4 |
| Ai, J | 1 |
| Cheng, X | 2 |
| Zhu, M | 1 |
| Liu, Q | 1 |
| Feng, Z | 1 |
| Yin, Z | 1 |
| Wang, L | 1 |
| Zhang, Y | 2 |
| Shan, T | 1 |
| Fröhlich, H | 1 |
| Torres, L | 1 |
| Täger, T | 1 |
| Schellberg, D | 1 |
| Corletto, A | 1 |
| Kazmi, S | 1 |
| Goode, K | 1 |
| Grundtvig, M | 1 |
| Hole, T | 1 |
| Katus, HA | 1 |
| Cleland, JGF | 1 |
| Atar, D | 1 |
| Clark, AL | 2 |
| Agewall, S | 1 |
| Frankenstein, L | 1 |
| Huang, J | 3 |
| Liu, X | 2 |
| Takayanagi, R | 1 |
| Fujito, K | 1 |
| Kimura, K | 1 |
| Yamada, Y | 1 |
| Sun, L | 2 |
| Yan, S | 1 |
| Wang, X | 2 |
| Zhao, S | 1 |
| Li, H | 1 |
| Wang, Y | 2 |
| Lu, S | 1 |
| Dong, X | 1 |
| Yu, S | 1 |
| Li, M | 1 |
| Dai, H | 1 |
| Yuan, Y | 1 |
| Yin, S | 1 |
| Han, Y | 1 |
| Li, T | 1 |
| Xu, J | 1 |
| Sheng, L | 1 |
| Gong, Y | 1 |
| Gasanov, I | 1 |
| Rudyk, Y | 1 |
| Batty, JA | 1 |
| Hall, AS | 1 |
| White, HL | 1 |
| Wikstrand, J | 5 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 3 |
| van der Harst, P | 1 |
| Waagstein, F | 4 |
| Hjalmarson, Å | 5 |
| Kjekshus, J | 5 |
| Balmforth, AJ | 1 |
| Bernhard, MK | 1 |
| Bertsche, A | 1 |
| Syrbe, S | 1 |
| Weise, S | 1 |
| Merkenschlager, A | 1 |
| Trappanese, DM | 1 |
| Liu, Y | 1 |
| McCormick, RC | 1 |
| Cannavo, A | 1 |
| Nanayakkara, G | 1 |
| Baskharoun, MM | 1 |
| Jarrett, H | 1 |
| Woitek, FJ | 1 |
| Tillson, DM | 1 |
| Dillon, AR | 1 |
| Recchia, FA | 1 |
| Balligand, JL | 1 |
| Houser, SR | 1 |
| Koch, WJ | 2 |
| Dell'Italia, LJ | 2 |
| Tsai, EJ | 1 |
| Ye, Y | 1 |
| Gong, H | 1 |
| Wu, J | 1 |
| Wang, S | 1 |
| Yuan, J | 1 |
| Yin, P | 1 |
| Jiang, G | 1 |
| Ding, Z | 1 |
| Zhang, W | 1 |
| Zhou, J | 1 |
| Ge, J | 1 |
| Zou, Y | 1 |
| Sahoo, D | 1 |
| Kapoor, A | 1 |
| Sinha, A | 1 |
| Khanna, R | 1 |
| Kumar, S | 1 |
| Garg, N | 1 |
| Tewari, S | 1 |
| Goel, P | 1 |
| Broch, K | 1 |
| Urheim, S | 1 |
| Massey, R | 1 |
| Stueflotten, W | 1 |
| Fosså, K | 1 |
| Hopp, E | 1 |
| Aakhus, S | 1 |
| Gullestad, L | 3 |
| Liu, J | 1 |
| Tregubov, VG | 1 |
| Kanorskiy, SG | 1 |
| Pokrovskiy, VM | 1 |
| Rengo, G | 1 |
| Lymperopoulos, A | 1 |
| Zincarelli, C | 1 |
| Donniacuo, M | 1 |
| Soltys, S | 1 |
| Rabinowitz, JE | 1 |
| Björkander, I | 3 |
| Forslund, L | 3 |
| Ericson, M | 1 |
| Rehnqvist, N | 3 |
| Hjemdahl, P | 3 |
| Kahan, T | 1 |
| Ghali, JK | 1 |
| Fagerberg, B | 2 |
| Goldstein, S | 3 |
| Johansson, P | 1 |
| Ohlsson, L | 1 |
| Samuelsson, O | 1 |
| Wedel, H | 3 |
| Solov'ev, OV | 1 |
| Efremov, DN | 1 |
| Onuchina, EL | 1 |
| Solov'eva, NV | 1 |
| Kononov, SV | 1 |
| Lü, HS | 1 |
| He, BB | 1 |
| Huang, GH | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 1 |
| Keogh, AM | 1 |
| Kotlyar, E | 1 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Krum, H | 1 |
| Hayward, CS | 1 |
| Gao, WQ | 1 |
| Han, CG | 1 |
| Zhao, YX | 1 |
| Wang, Q | 1 |
| Zhu, P | 1 |
| Yang, TS | 1 |
| Liu, YX | 1 |
| Baudhuin, LM | 1 |
| Miller, WL | 1 |
| Train, L | 1 |
| Bryant, S | 1 |
| Hartman, KA | 1 |
| Phelps, M | 1 |
| Larock, M | 1 |
| Jaffe, AS | 1 |
| Zhang, ZW | 1 |
| Lin, ZP | 1 |
| Dhein, S | 1 |
| Rothe, S | 1 |
| Busch, A | 1 |
| Rojas Gomez, DM | 1 |
| Boldt, A | 1 |
| Reutemann, A | 1 |
| Seidel, T | 1 |
| Salameh, A | 1 |
| Pfannmüller, B | 1 |
| Rastan, A | 1 |
| Kostelka, M | 1 |
| Mohr, FW | 1 |
| Ozova, EM | 1 |
| Kiiakbaev, GK | 1 |
| Kobalava, ZhD | 1 |
| Moiseev, VS | 1 |
| Kar, S | 1 |
| Gao, L | 2 |
| Belatti, DA | 1 |
| Curry, PL | 2 |
| Zucker, IH | 4 |
| Leung, AA | 1 |
| Ghali, WA | 1 |
| Haas, DM | 1 |
| DʼAlton, M | 1 |
| Haack, KK | 1 |
| Schiller, AM | 1 |
| Pellegrino, PR | 1 |
| Fung, JW | 1 |
| Chan, SK | 1 |
| Yeung, LY | 1 |
| Sanderson, JE | 1 |
| Metra, M | 4 |
| Nodari, S | 1 |
| D'Aloia, A | 1 |
| Muneretto, C | 1 |
| Robertson, AD | 2 |
| Bristow, MR | 3 |
| Dei Cas, L | 1 |
| Groenning, BA | 1 |
| Nilsson, JC | 1 |
| Hildebrandt, PR | 1 |
| Kjaer, A | 1 |
| Fritz-Hansen, T | 1 |
| Larsson, HB | 1 |
| Sondergaard, L | 1 |
| Bruns, LA | 1 |
| Canter, CE | 1 |
| Vittorio, TJ | 2 |
| Lang, CC | 1 |
| Katz, SD | 3 |
| Packer, M | 2 |
| Mancini, DM | 1 |
| Jorde, UP | 2 |
| Ushkvarok, LB | 1 |
| Maggioni, AP | 1 |
| Sinagra, G | 1 |
| Opasich, C | 1 |
| Geraci, E | 1 |
| Gorini, M | 1 |
| Gronda, E | 1 |
| Lucci, D | 1 |
| Tognoni, G | 1 |
| Balli, E | 1 |
| Tavazzi, L | 1 |
| Morita, H | 1 |
| Suzuki, G | 1 |
| Mishima, T | 1 |
| Chaudhry, PA | 1 |
| Anagnostopoulos, PV | 1 |
| Tanhehco, EJ | 1 |
| Sharov, VG | 1 |
| Sabbah, HN | 1 |
| Pliquett, RU | 1 |
| Cornish, KG | 2 |
| Bollano, E | 1 |
| Täng, MS | 2 |
| Andersson, B | 2 |
| Bouzamondo, A | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 1 |
| Hryniewicz, K | 2 |
| Androne, AS | 2 |
| Hudaihed, A | 2 |
| Witte, KK | 1 |
| Thackray, SD | 1 |
| Nikitin, NP | 1 |
| Cleland, JG | 5 |
| Swedberg, K | 5 |
| Syrkin, AL | 3 |
| Kukes, VG | 1 |
| Poltavskaia, MG | 3 |
| Andreev, DA | 2 |
| Aref'eva, AB | 1 |
| Teplonogova, EV | 1 |
| Konova, IA | 1 |
| Rykova, MS | 1 |
| Gupta, R | 2 |
| Tang, WH | 1 |
| Young, JB | 1 |
| Ertl, G | 1 |
| Nitschmann, S | 1 |
| Ebbehøj, E | 1 |
| Arildsen, H | 1 |
| Hansen, KW | 1 |
| Mogensen, CE | 1 |
| Mølgaard, H | 1 |
| Poulsen, PL | 1 |
| Höcht, C | 1 |
| Di Verniero, C | 1 |
| Opezzo, JA | 1 |
| Taira, CA | 1 |
| Ahmed, A | 1 |
| Liu, XF | 1 |
| Patel, KP | 1 |
| Plante, E | 2 |
| Lachance, D | 2 |
| Gaudreau, M | 1 |
| Drolet, MC | 2 |
| Roussel, E | 2 |
| Arsenault, M | 2 |
| Couet, J | 2 |
| Hoogendoorn, EH | 1 |
| Cools, BM | 1 |
| Deedwania, P | 1 |
| Egstrup, K | 1 |
| Elkayam, U | 1 |
| Gottlieb, S | 1 |
| Rashkow, A | 1 |
| Bermann, G | 1 |
| Murakami, T | 1 |
| Torp-Pedersen, C | 3 |
| Di Lenarda, A | 2 |
| Komajda, M | 3 |
| Remme, WJ | 3 |
| Lutiger, B | 1 |
| Scherhag, A | 2 |
| Lukas, MA | 1 |
| Charlesworth, A | 3 |
| Poole-Wilson, PA | 2 |
| Ekman, I | 1 |
| Andersson, G | 1 |
| Boman, K | 1 |
| Poole-Wilson, P | 2 |
| Schwarz, ER | 1 |
| Diep, TP | 1 |
| Nowak, B | 1 |
| Kostin, S | 1 |
| Grohmann, B | 1 |
| Uretsky, BF | 1 |
| Schaper, J | 1 |
| Molchanova, IV | 1 |
| Churganova, LIu | 1 |
| Chaplygin, AV | 1 |
| Aquilante, CL | 1 |
| Terra, SG | 1 |
| Schofield, RS | 1 |
| Pauly, DF | 1 |
| Hatton, PS | 1 |
| Binkley, PF | 1 |
| Johnson, JA | 1 |
| Lubsen, J | 1 |
| Erhardt, L | 1 |
| Cocco, G | 1 |
| Chu, D | 1 |
| Berlowitz, DR | 1 |
| Miller, DR | 1 |
| Oliveria, SA | 1 |
| Cunningham, F | 1 |
| Gomez-Caminero, A | 1 |
| Rothendler, JA | 1 |
| Köhnlein, T | 1 |
| Welte, T | 1 |
| De Freitas, O | 1 |
| Lenz, O | 1 |
| Fornoni, A | 1 |
| Materson, BJ | 1 |
| Karaca, I | 1 |
| Coşkun, N | 1 |
| Yavuzkir, M | 1 |
| Ilkay, E | 1 |
| Dağli, N | 1 |
| Işik, A | 1 |
| Balin, M | 1 |
| Akbulut, M | 1 |
| Arslan, N | 1 |
| Zhao, Q | 1 |
| Wu, TG | 1 |
| Jiang, ZF | 1 |
| Chen, GW | 1 |
| Lin, Y | 1 |
| Wang, LX | 1 |
| Aneja, P | 1 |
| Srinivas, A | 1 |
| Biswas, AD | 1 |
| Beliaev, AM | 1 |
| Smith, W | 1 |
| Svet, AV | 1 |
| Sarkisova, EA | 1 |
| Kalashnikov, VIu | 1 |
| Olsson, LG | 1 |
| Spark, PA | 1 |
| Tomcsányi, J | 1 |
| Wettstein, A | 1 |
| Toldy-Schedel, E | 1 |
| Somlói, M | 1 |
| Li, JJ | 1 |
| Qu, XF | 1 |
| Li, KS | 1 |
| Yu, Y | 1 |
| Xi, Y | 1 |
| Yue, L | 1 |
| Wang, GZ | 1 |
| Huang, YL | 1 |
| Zolty, R | 1 |
| Kasper, ME | 1 |
| Khandwalla, RM | 1 |
| Hirsh, DS | 1 |
| Tseng, CH | 1 |
| Ahuja, K | 1 |
| Champetier, S | 1 |
| Lessem, J | 1 |
| Currie, PJ | 1 |
| Kelly, MJ | 1 |
| McKenzie, A | 1 |
| Harper, RW | 1 |
| Lim, YL | 1 |
| Federman, J | 1 |
| Anderson, ST | 1 |
| Pitt, A | 1 |
| Armaganijan, D | 1 |
| Batlouni, M | 1 |
| Fenster, PE | 1 |
| Hasan, FM | 1 |
| Abraham, T | 1 |
| Woolfenden, J | 1 |
| Bogaert, MG | 1 |
| Clement, DL | 1 |
| Myers, MG | 1 |
| Iazzetta, JJ | 1 |
| Santostasi, G | 2 |
| Marinato, PG | 2 |
| Miraglia, G | 2 |
| Egloff, C | 2 |
| Maragno, I | 2 |
| López Candel, J | 1 |
| Picó Aracil, F | 1 |
| Sánchez Muñoz, JJ | 1 |
| de la Morena, G | 1 |
| Martínez Sánchez, J | 1 |
| Salas, J | 1 |
| Campos Peris, JV | 1 |
| Ruiz Ros, JA | 1 |
| García García, J | 1 |
| Jaén Armand, E | 1 |
| Kukin, ML | 2 |
| Kalman, J | 2 |
| Mannino, M | 1 |
| Freudenberger, R | 1 |
| Buchholz, C | 1 |
| Ocampo, O | 1 |
| Okamoto, M | 1 |
| Miyazaki, H | 1 |
| Tsuzuki, M | 1 |
| Ino, T | 1 |
| Ezaki, K | 1 |
| Hirano, M | 1 |
| Cheng, DC | 1 |
| Jiang, MT | 1 |
| Asokumar, B | 1 |
| Boylen, P | 1 |
| Sandler, A | 1 |
| Di Somma, S | 1 |
| de Divitiis, M | 1 |
| Bertocchi, F | 1 |
| Carotenuto, A | 1 |
| Cudemo, G | 1 |
| Petitto, M | 1 |
| Napodano, M | 1 |
| de Divitiis, O | 1 |
| Abraham, WT | 1 |
| Yoshikawa, T | 1 |
| White, M | 1 |
| Hattler, BG | 1 |
| Crisman, TS | 1 |
| Lowes, BD | 1 |
| Larrabee, P | 1 |
| Gilbert, EM | 1 |
| Fraccarollo, D | 1 |
| Dorigo, P | 1 |
| Villanova, C | 1 |
| Fasoli, G | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Charney, RH | 1 |
| Levy, DK | 1 |
| Buchholz-Varley, C | 1 |
| Ocampo, ON | 1 |
| Eng, C | 1 |
| vom Dahl, J | 1 |
| Schotten, U | 1 |
| Sasse, A | 1 |
| Held, C | 2 |
| Eriksson, SV | 2 |
| Brodin, U | 1 |
| Hart, SM | 1 |
| Tjeerdsma, G | 1 |
| Szabó, BM | 1 |
| van Wijk, LM | 1 |
| Brouwer, J | 1 |
| Tio, RA | 1 |
| Crijns, HJ | 1 |
| Bilge, M | 1 |
| Güler, N | 1 |
| Eryonucu, B | 1 |
| Erkoç, R | 1 |
| Kochiadakis, GE | 1 |
| Kanoupakis, EM | 1 |
| Kalebubas, MD | 1 |
| Igoumenidis, NE | 1 |
| Vardakis, KE | 1 |
| Mavrakis, HE | 1 |
| Vardas, PE | 1 |
| Manhenke, C | 1 |
| Aarsland, T | 1 |
| Skårdal, R | 1 |
| Fagertun, H | 1 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Maack, C | 1 |
| Elter, T | 1 |
| Nickenig, G | 1 |
| LaRosee, K | 1 |
| Crivaro, M | 1 |
| Stäblein, A | 1 |
| Wuttke, H | 1 |
| Böhm, M | 1 |
| Azevedo, ER | 2 |
| Kubo, T | 2 |
| Mak, S | 1 |
| Al-Hesayen, A | 1 |
| Schofield, A | 1 |
| Allan, R | 1 |
| Kelly, S | 1 |
| Newton, GE | 2 |
| Floras, JS | 2 |
| Parker, JD | 2 |
| Hirooka, K | 1 |
| Yasumura, Y | 1 |
| Ishida, Y | 1 |
| Hanatani, A | 1 |
| Nakatani, S | 1 |
| Komamura, K | 1 |
| Hori, M | 1 |
| Yamagishi, M | 1 |
| Miyatake, K | 1 |
| Sveälv, BG | 1 |
| Mobini, R | 1 |
| Zaglavara, T | 1 |
| Haaverstad, R | 1 |
| Cumberledge, B | 1 |
| Irvine, T | 1 |
| Karvounis, H | 1 |
| Parharidis, G | 1 |
| Louridas, G | 1 |
| Kenny, A | 1 |
| Hua, AS | 1 |
| Assaykeen, TA | 1 |
| Nyberg, G | 1 |
| Kincaid-Smith, PS | 1 |
| McGavin, CR | 1 |
| Williams, IP | 1 |
| Krieglstein, GK | 1 |
| Khalsa, A | 1 |
| Edvardsson, N | 1 |
| Olsson, SB | 1 |
| Tivenius, L | 1 |
| Lopatin, IuM | 1 |
| Ghani, P | 1 |
| Sinitsin, VE | 1 |
| Mareev, VIu | 1 |
| Paolisso, G | 1 |
| Gambardella, A | 1 |
| Marrazzo, G | 1 |
| Verza, M | 1 |
| Teasuro, P | 1 |
| Varricchio, M | 1 |
| D'Onofrio, F | 1 |
| Sachdev, P | 1 |
| Chee, KY | 1 |
| Nemanich, JW | 1 |
| Veith, RC | 1 |
| Abrass, IB | 1 |
| Stratton, JR | 1 |
| Kim, A | 1 |
| Adler, L | 1 |
| Angrist, B | 1 |
| Rotrosen, J | 1 |
| Franz, IW | 1 |
| Wiewel, D | 1 |
| Behr, M | 1 |
| Ketelhut, R | 1 |
| Suenaga, N | 1 |
| Hayashi, F | 1 |
| Kataoka, Y | 1 |
| Miyauchi, N | 1 |
| Nishioka, Y | 1 |
| Kurosu, I | 1 |
| Kitada, O | 1 |
| Sugita, M | 1 |
| del Nero, E | 1 |
| Yasbek Júnior, P | 1 |
| Kedor, H | 1 |
| Kiss, MA | 1 |
| Juliano, Y | 1 |
| Moffa, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure[NCT01971944] | 50 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment[NCT03387605] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-03-15 | Recruiting | ||
| Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients[NCT01502787] | Phase 4 | 46 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF 1[NCT04882449] | 300 participants (Anticipated) | Interventional | 2021-07-08 | Active, not recruiting | |||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01502787)
Timeframe: 12 weeks after initiation of metoprolol
| Intervention | mmHg (Mean) |
|---|---|
| Metoprolol | 114 |
| Nebivolol | 113 |
(NCT01502787)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Initial Treatment With Metoprolol | 101 |
| Initial Treatment With Nebivolol | 103 |
(NCT01502787)
Timeframe: 12 weeks after each specified medication
| Intervention | ml/min (Mean) |
|---|---|
| First Intervention Metoprolol: 12 Weeks | 96 |
| Second Intervention Nebivolol: 24 Weeks | 105 |
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
11 reviews available for metoprolol and Chronic Disease
| Article | Year |
|---|---|
Appreciating the medical literature: five notable articles in general internal medicine from 2009 and 2010.
Topics: Aged; Anti-Arrhythmia Agents; Anticholesteremic Agents; Atrial Fibrillation; Blood Pressure; Cardiov | 2011 |
Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Chronic Di | 2002 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinical Trials as | 2003 |
Use of beta-blockers in older adults with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiovascu | 2004 |
[Beta blockers for therapy of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as | 2005 |
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Delayed-Action Preparations; D | 2006 |
[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Bisoprolol; Carbazoles | 1999 |
beta-adrenergic receptor blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hea | 2000 |
Influence of beta-blockers on mortality in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2000 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
61 trials available for metoprolol and Chronic Disease
| Article | Year |
|---|---|
Impact of metoprolol treatment on cardiac function and exercise tolerance in heart failure patients with neuropsychiatric disorders.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Chronic Disease; Exercise Tolerance; Female; Hear | 2018 |
An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Chronic Disease; Cytochrome P-450 CYP2D6; DNA; Do | 2014 |
Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers.
Topics: Administration, Oral; Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Biomarkers; Chronic | 2016 |
A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Output; China; Chronic Disease; Female; Heart Failure; Heart R | 2017 |
Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Coron | 2009 |
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Feeding Behavior; Female; Glomerular Filtration | 2009 |
[Therapeutic effects of amiodarone and metoprolol on chronic heart failure complicated by ventricular arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Chronic Disease; Drug Therap | 2009 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvasta | 2011 |
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow | 2002 |
Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biological Factors; Biomarkers; Blood P | 2002 |
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting En | 2003 |
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Chronic Disease; Cross-Over | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazo | 2003 |
The effects of alpha and beta blockade on ventilatory responses to exercise in chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output, Low; Chro | 2003 |
Effects of metoprolol on QT interval and QT dispersion in Type 1 diabetic patients with abnormal albuminuria.
Topics: Administration, Oral; Adult; Albuminuria; Chronic Disease; Cross-Over Studies; Denmark; Diabetes Mel | 2004 |
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Chronic Disease; Delayed-Action Prepara | 2005 |
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Dose-Response | 2005 |
Carvedilol improves myocardial contractility compared with metoprolol in patients with chronic hibernating myocardium after revascularization.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Apoptosis; Carbazoles; Carvedilol; Chronic Disease; Corona | 2005 |
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Autonomic Nervous System; Blood Pressure; Chronic Disease; Cross- | 2006 |
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Diu | 2006 |
Effect of diltiazem and metoprolol on left atrial appendix functions in patients with nonvalvular chronic atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Atrial F | 2007 |
Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Chronic Di | 2007 |
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin].
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; | 2007 |
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; H | 2007 |
Switching beta-blocker therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Chronic Disease; Heart Failure; Humans; Metoprolol | 2008 |
Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Dr | 2008 |
Beta-blocker therapy evaluated by radionuclide angiography: a study in chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Cardiac Volume; Chronic Disease; Echoc | 1982 |
Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiomyopathy, Dila | 1984 |
[Evaluation of the effects of slow-release metoprolol in chronic coronary insufficiency].
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Delayed-Action Preparations; Dou | 1983 |
Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease.
Topics: Adult; Chronic Disease; Female; Heart Ventricles; Humans; Lung Diseases, Obstructive; Lung Volume Me | 1983 |
Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication.
Topics: Chronic Disease; Exercise Test; Humans; Intermittent Claudication; Male; Metoprolol; Middle Aged; Pr | 1983 |
Intranasally administered phenylephrine and blood pressure.
Topics: Administration, Intranasal; Adult; Blood Pressure; Chronic Disease; Drug Interactions; Heart Rate; H | 1982 |
Influence of beta-blockade with metoprolol on symptoms and functional capacity of patients with idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chronic Disease; Exercise Test; Exercise Tolerance; Female; He | 1994 |
Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Chronic Disease; Doxazosin; | 1996 |
Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.
Topics: Angina Pectoris; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blo | 1996 |
Second- and third-generation beta-blocking drugs in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; | 1997 |
Early reduction in plasma norepinephrine during beta-blocking therapy with metoprolol in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Chronic Disease; Echocardiography; Exercise Te | 1998 |
Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazoles; Carv | 1998 |
Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disea | 1999 |
Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Elect | 1999 |
Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Exerc | 2000 |
Autonomic dysfunction in patients with mild heart failure and coronary artery disease and the effects of add-on beta-blockade.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Autonomic Nervous System; Case-Control Stu | 2001 |
Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Circadian | 2001 |
Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial.
Topics: Aged; Chronic Disease; Confidence Intervals; Delayed-Action Preparations; Double-Blind Method; Drug | 2001 |
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Cross-Over Studies; Female; He | 2001 |
Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; | 2001 |
Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2001 |
Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazoles; Ca | 2001 |
Longitudinal myocardial contraction improves early during titration with metoprolol CR/XL in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Catecholamines; Chronic Disease; Delayed-Action Preparations; Diastole; | 2002 |
Results from a multicentre trial of metoprolol and a study of hypertensive patients with chronic obstructive lung disease.
Topics: Adult; Aged; Antihypertensive Agents; Asthma; Chronic Disease; Clinical Trials as Topic; Drug Therap | 1978 |
The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction.
Topics: Administration, Oral; Aged; Airway Obstruction; Chronic Disease; Clinical Trials as Topic; Double-Bl | 1978 |
The effect of metoprolol on IOP (author's transl).
Topics: Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Gl | 1978 |
Effects of muliple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, | 1976 |
[Potential possibilities of using adrenergic beta blockers in chronic heart failure].
Topics: Adolescent; Adult; Aged; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Metopro | 1992 |
Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure.
Topics: Aged; Blood Glucose; Chronic Disease; Double-Blind Method; Fatty Acids, Nonesterified; Female; Gluco | 1992 |
Pharmacological characterization of tardive akathisia.
Topics: Administration, Oral; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Arousal; Atenolol; Benztr | 1990 |
[Effect of metoprolol duriles in chronic coronary insufficiency].
Topics: Adult; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Delayed-Action P | 1985 |
58 other studies available for metoprolol and Chronic Disease
| Article | Year |
|---|---|
Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Antihypertensive Agents; Betaxolol; Biotra | 1987 |
Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients.
Topics: Adult; Aged; Anxiety; Asian People; China; Chronic Disease; Depression; Female; Heart Failure; Heart | 2019 |
Metoprolol prevents neuronal dendrite remodeling in a canine model of chronic obstructive sleep apnea.
Topics: Animals; Chronic Disease; Dendrites; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; | 2020 |
Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study.
Topics: Administration, Oral; Aged; Asian People; Chronic Disease; Female; Heart Failure; Humans; Male; Meto | 2020 |
Evaluation of ultrasonic indexes and exercise endurance application of diuretic mixture combined with metoprolol in the treatment of senile chronic heart failure.
Topics: Adrenergic beta-Antagonists; Chronic Disease; Diuretics; Heart Failure; Humans; Metoprolol; Ultrason | 2022 |
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2017 |
Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Forced Expiratory | 2017 |
Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria.
Topics: Adrenergic beta-1 Receptor Antagonists; AMP-Activated Protein Kinase Kinases; Animals; Atrial Fibril | 2017 |
Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Anxiety; Chronic Disease; Depression; Female; Heart; Hea | 2019 |
Improvement in quality of life of Chinese chronic heart failure patients with neuropsychiatric complications over 12-months post-treatment with metoprolol.
Topics: Aged; Anti-Arrhythmia Agents; Anxiety; China; Chronic Disease; Depression; Female; Heart Failure; Hu | 2019 |
Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea.
Topics: Adipokines; Adipose Tissue; Animals; Cardiomyopathies; Chronic Disease; Disease Models, Animal; Dogs | 2019 |
METOPROLOL SUCCINATE: GENETIC ASPECTS OF INDIVIDUAL SENSITIVITY AND EFFICACY IN PATIENTS WITH OBESITY AND CHRONIC HEART FAILURE.
Topics: Adrenergic beta-Antagonists; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Met | 2019 |
[Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
Topics: Adolescent; Adrenergic beta-Antagonists; Botulinum Toxins, Type A; Chronic Disease; Female; Fructose | 2014 |
Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Chronic Disease; Cyclic GMP; Dogs; Ethanolamines; G | 2015 |
Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2015 |
Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aortic Valve Insufficiency; Asympto | 2016 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; | 2016 |
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Catecholamines; Chronic Disease; Dependovirus; Di | 2009 |
[The use of metoprolol tartrate during restoration of sinus rhythm and its subsequent maintenance in patients with chronic atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Drug; | 2009 |
[Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure].
Topics: Aged, 80 and over; Chronic Disease; G-Protein-Coupled Receptor Kinase 2; Heart Failure; Humans; Lymp | 2010 |
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Carbazoles; Carvedilol; Chronic Disease; Comorbidity; Cy | 2010 |
[Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure, serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Pressure; C-Reactive Protein; Chronic Di | 2010 |
Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation.
Topics: Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Chronic Disease; Connexin 43; Connexins | 2011 |
Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Chronic Disease; Consci | 2011 |
Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?
Topics: Antihypertensive Agents; Chronic Disease; Cytochrome P-450 CYP2D6; Drug Substitution; Female; Humans | 2012 |
Central Rho kinase inhibition restores baroreflex sensitivity and angiotensin II type 1 receptor protein imbalance in conscious rabbits with chronic heart failure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Brain Stem; Chronic Disease; Con | 2013 |
[Stability of neurohumoral effects of losartan combined with metoprolol in chronic cardiac low output].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; | 2002 |
Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic | 2003 |
Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Dogs; Female; Fibrosis; Heart Diseases; Heart | 2002 |
Statin therapy restores sympathovagal balance in experimental heart failure.
Topics: Animals; Atropine; Baroreflex; Cardiac Output, Low; Chronic Disease; Heart Rate; Hemodynamics; Hydro | 2003 |
[The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Metopro | 2003 |
[Effect of beta-blockers metoprolol CR/XL and carvedilol on left ventricular contractility in patients with chronic low cardiac output].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Chronic Disease; Drug Admi | 2003 |
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ambulatory Care Facilities; Carbazoles; Carvedilol; | 2004 |
Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Biomarkers; Blood Pressure; Body Weight; Cachexia; Carbazoles; Carvedil | 2003 |
[Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Chronic Disease; Double-Blind M | 2004 |
Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats.
Topics: Animals; Aortic Coarctation; Blood Pressure; Bradycardia; Chronic Disease; Disease Models, Animal; D | 2004 |
Effects of nNOS antisense in the paraventricular nucleus on blood pressure and heart rate in rats with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atropine; Blood Pressure; Blotti | 2005 |
Effectiveness of beta-blockade in experimental chronic aortic regurgitation.
Topics: Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Catecholamines; Cell Size; Chronic | 2004 |
Hyperthyroidism as a cause of persistent vomiting.
Topics: Abdominal Pain; Adrenergic beta-Antagonists; Adult; Chronic Disease; Diagnosis, Differential; Female | 2004 |
Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Varian | 2006 |
[Muscular mechanisms of lowering of physical working capacity in chronic heart failure and action of beta-adrenoblockers].
Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Exercise Test; Female; Heart Rate; Humans; Male; | 2005 |
The anti-ischemic effect of metoprolol in patients with chronic angina pectoris is gender-specific.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Chronic Disease; Exercise Test; | 2006 |
Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atenolol | 2006 |
Does beta-blocker treatment influence central sleep apnoea?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Cardiomyopathy, Dilated; Carvedilol; C | 2007 |
Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Gene | 2007 |
Metoprolol-induced hyperkalaemia in chronic respiratory acidosis.
Topics: Acidosis, Respiratory; Adrenergic beta-Antagonists; Adult; Chronic Disease; Cross-Sectional Studies; | 2007 |
[Effect of chronic myocardial infarction on the distribution of beta-adrenoceptors in heart: experiment with dogs].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2007 |
Benefits of long-term beta-blockade in experimental chronic aortic regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2008 |
[Malignant vasovagal syncope: its diagnosis and therapeutic trial based on the orthostatism test (the tilt-table test)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Clonidine; Female; Heart Functio | 1993 |
[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
Topics: Aclarubicin; Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Cardiomyopathy, Hypert | 1995 |
Comparison of nifedipine and metoprolol on collateral coronary blood flow in a swine model of chronic coronary obstruction and acute ischaemia during isoflurane anaesthesia.
Topics: Adrenergic beta-Antagonists; Anesthetics, Inhalation; Animals; Calcium Channel Blockers; Chronic Dis | 1996 |
Does acute-phase beta blockade reduce left atrial appendage function in patients with chronic nonvalvular atrial fibrillation?
Topics: Adrenergic beta-Antagonists; Adult; Atrial Appendage; Atrial Fibrillation; Chronic Disease; Echocard | 2001 |
Dobutamine stress echocardiography for the detection of myocardial viability in patients with left ventricular dysfunction taking beta blockers: accuracy and optimal dose.
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiotonic Agents; Chronic Disease; Coronary Artery Bypass; | 2002 |
Effects of metoprolol on heart rate in patients with digitalis treated chronic atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides; Drug Therapy, Combination; | 1978 |
Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy.
Topics: Aged; Cardiomyopathy, Dilated; Catecholamines; Chronic Disease; Coronary Disease; Epinephrine; Exerc | 1990 |
Efficacy of low-dose metoprolol in neuroleptic-induced akathisia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, D | 1989 |
[Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block].
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiomegaly; Carvedilol; Chronic Di | 1986 |
[A case of chronic hyperventilation syndrome effectively treated by metoprolol].
Topics: Adult; Chronic Disease; Diazepam; Drug Therapy, Combination; Female; Humans; Hyperventilation; Metop | 1988 |